The U.S. Food and Drug Administration (FDA) on Thursday announced the recall of a thyroid medication after it was found that lots of the drug may be “subpotent.”
IBSA Pharma Inc. confirmed it is recalling Tirosint-SOL, or levothyroxine sodium, a medication used to treat an underactive thyroid gland. It said that the “voluntary recall has been initiated because these lots may be subpotent,” stated the announcement, published on the FDA’s website.
“The company’s analyses show a slight decrease below 95.0 percent of its labeled amount in levothyroxine sodium (T4) for some lots,” according to the recall notice. The recall doesn’t apply to Tirosint capsules….
-
Recent Posts
-
Archives
- May 2025
- April 2025
- July 2023
- June 2023
- May 2023
- April 2023
- March 2023
- February 2023
- January 2023
- December 2022
- November 2022
- October 2022
- September 2022
- August 2022
- July 2022
- June 2022
- May 2022
- April 2022
- March 2022
- February 2022
- January 2022
- December 2021
- November 2021
- October 2021
- September 2021
- August 2021
- July 2021
- June 2021
- May 2021
- April 2021
- March 2021
- February 2021
- January 2021
- December 2020
- September 2013
- July 2013
- March 2013
- January 2013
- December 2012
- November 2012
- December 1
-
Meta